Navigation Links
Juvenile Diabetes Research Foundation Names Monye Connolly Corporate Chair for its Annual Walk to Cure Diabetes
Date:3/4/2009

The 2009 Walk to Cure Diabetes will be held Saturday, October 17 at

Centennial Olympic Park

ATLANTA, March 4 /PRNewswire/ -- The Georgia Chapter of the Juvenile Diabetes Research Foundation (JDRF) has announced that Blue Cross and Blue Shield of Georgia (BCBSGa) President, Monye Connolly, will serve as the Corporate Chair for its annual, and largest, fundraising event, Walk to Cure Diabetes. The event is scheduled in Atlanta at Centennial Olympic Park on Saturday, Oct. 17, 2009.

Last year's walk raised more than $1.5 million to fund research to help find a cure for diabetes.

"The Juvenile Diabetes Research Foundation is firm in its commitment to finding a cure for diabetes and its complications through the support of research. BCBSGa truly believes in JDRF and its mission, which supports our mission of improving the lives of the people we serve and the health of our communities," said Connolly.

"We look forward to working with Monye Connolly in the months to come to make the 2009 Walk our best one ever. As someone with type 1 diabetes myself, it is very gratifying to have the support of such a large, successful company in our relentless goal to find a cure for diabetes and its complications," said Kris Bagwell, JDRF Georgia Board President

As many as 3 million people in the U.S. are now living with type 1 diabetes. Each year more than 15,000 children are diagnosed with diabetes - that's 40 children per day. More than 85 percent of JDRF's expenditures directly support research and research-related education.

Corporate sponsorships, corporate Walk Teams and Family Walk Teams will be the key to the success of the Walk to Cure Diabetes. For more information about JDRF, the critical research they fund and how you can help, call 404-420-5990, or visit www.jdrf.org.

About JDRF:

JDRF was founded in 1970 by the parents of children with type-1 diabetes - a disease that strikes children, adolescents and adults suddenly, making them insulin dependent for life, which carries the constant threat of devastating complications. Since inception, JDRF has provided more than $1.3 billion to diabetes research worldwide. More than 85 percent of JDRF's expenditures directly support research and research-related education. JDRF's mission is constant: to find a cure for diabetes and its complications through the support of research. To register now and participate, sponsor an event, build a walk team, or for more information, please visit www.jdrf.org, or call 404-420-5990.

About Blue Cross Blue Shield of Georgia:

Blue Cross and Blue Shield of Georgia, Inc. and Blue Cross and Blue Shield Healthcare Plan of Georgia, Inc. are independent licensees of the Blue Cross and Blue Shield Association(R) . The Blue Cross and Blue Shield names and symbols are registered marks of the Blue Cross and Blue Shield Association. Additional information about Blue Cross and Blue Shield of Georgia is available at www.bcbsga.com.


'/>"/>
SOURCE Juvenile Diabetes Research Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Pennsylvanians May Donate Part of Tax Refund to Support Juvenile Diabetes Research
2. Etanercept, Methotrexate Safe for Juvenile RA
3. Second Annual Eye Ball Fights Juvenile Diabetes, Says Oklahoma Academy of Ophthalmology
4. University of South Florida receives new multimillion award to assess juvenile diabetes treatments
5. Drug May Ease Symptoms of Juvenile Arthritis
6. Pediatric researchers find possible master switch gene in juvenile arthritis
7. Early life infections increase the risk of rheumatoid arthritis and juvenile idiopathic arthritis
8. Specific mutations in the IL2RA gene associated with juvenile idiopathic arthritis
9. Chrysler LLC Vice Chairman and President Jim Press and His Wife Suwichada Serve as Honorary Co-Chairs of Annual Juvenile Diabetes Research Foundation Promise Ball
10. Study affirms effectiveness of medication for juvenile rheumatoid arthritis
11. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/28/2017)... ... ... Today, Bright Pink , a national breast and ovarian health non-profit ... proactively at a young age. 1 in 8 women will develop breast cancer ... can save lives-but only if young women are proactive with their health. Bright Pink’s ...
(Date:2/28/2017)... ... 2017 , ... Science-based sleep company Level Sleep ... HCI students, faculty, and alumni can acquire Level Sleep’s unique sleep system in ... community to receive educational content on sleep and proper biomechanics that will empower ...
(Date:2/28/2017)... ... 28, 2017 , ... Las Vegas Skin and Cancer Clinic (LVSCC) is proud ... 10, 2017, 4-7 pm PST. For more than six decades, LVSCC has provided the ... Rancho neighborhood, has been renovated to provide medical and cosmetic dermatological products and services. ...
(Date:2/28/2017)... ... February 28, 2017 , ... ... a healthcare automation intelligence company based in New York. , “Ensuring an intuitive, ... provider’s workflow remains unaltered. Those two fundamental reasons are the reasons this acquisition ...
(Date:2/28/2017)... ... February 28, 2017 , ... The role of females ... from military to civilian life. Body image dissatisfaction is largely unexamined among female ... and greater occurrence of chronic mental health conditions than female civilians. Female veterans ...
Breaking Medicine News(10 mins):
(Date:2/27/2017)... 27, 2017  A landmark study led ... MBBS, PhD, FRACS, of  Sydney Heart and Lung ... will be published in the February 28, 2017 issue ... College of Cardiology . According to the study, which involved 37,720 ... surgery technique (anOPCABG) reduced postoperative stroke by ...
(Date:2/27/2017)... TAMPA, Fla. , Feb. 27, ... medical device company focused on developing cerebral embolic ... the members of the FDA,s Circulatory System Devices ... acknowledgement of the need for cerebral protection following ... "The statements shared by this FDA panel support ...
(Date:2/27/2017)... -- Now in its seventh year, the Pharmaceutical ... successful at developing and commercialising innovation. ... The Index can be summarised ... two different companies in early phase, which would make the ... of each company,s performance between 2011 and 2016, the 2017 ranking sees ...
Breaking Medicine Technology: